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Background: As one of the future strategies of advanced pulmonary hypertension,
intrinsic prostacyclin drug delivery using gene therapy may be useful. We investi-
gated whether transfer of the prostacyclin synthase gene into the liver could
ameliorate monocrotaline-induced pulmonary hypertension in rats.
Methods: The human prostacyclin synthase gene was transfected into the liver of
rats with monocrotaline-induced pulmonary hypertension. Hemodynamic indices,
blood samples, lung tissues, and survival curves were evaluated between rats
receiving the gene and control rats.
Results: High levels of prostacyclin synthase gene expression were found in the
hepatocytes of the prostacyclin synthase group. The level of 6-keto-prostaglandin
F1 was significantly higher in the prostacyclin synthase group (prostacyclin syn-
thase, 35.4  4.4 ng/mL; control, 22.3  3.3 ng/mL; P  .0436). The right
ventricular/femoral artery pressure ratio was significantly lower in the prostacyclin
synthase group than in the control group (prostacyclin synthase, 0.60  0.039;
control, 0.88  0.051; P  .0036). The endothelin-1 levels in the lung tissues were
significantly lower in the prostacyclin synthase group than in the control group
(prostacyclin synthase, 10.42  2.01 pg/mg protein; control, 19.94  2.82 pg/mg
protein; P  .0176). The survival ratio was significantly higher in the prostacyclin
synthase group than the control group (P  .0375).
Conclusion: This drug delivery system using gene transfer can be considered as an
alternative for continuous intravenous prostacyclin infusion for pulmonary hyper-
tension.
Primary pulmonary hypertension is a life-threatening disease charac-terized by progressive pulmonary hypertension and right ventricularfailure, resulting in death. To date, there is no lifesaving treatmentwithout lung transplantation. Recently, the intravenous administrationof prostacyclin, a short-acting vasodilator, was shown to improve thehemodynamics and symptoms of patients with primary or secondary
pulmonary hypertension associated with congenital heart defects.1-4 However, it is
difficult to maintain a continuous intravenous administration of this drug over the
long term, especially in children, because of clinical problems such as vessel access,
infections, and low quality of life. Thus, the availability of alternative strategies,
including gene therapy, would be beneficial for patients with critical pulmonary
hypertension.
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Prostacyclin synthase (PGIS) catalyzes the conversion of
prostaglandin H2 to prostacyclin.5 Recently, we determined
the amino acid sequence of bovine and human endothelial
PGIS by complementary DNA cloning6-9 and showed that
transfection of the human PGIS gene could increase the
amount of prostacyclin production in rats.10 Therefore, the
transfection of the human PGIS gene might provide a novel
therapy for treating pulmonary hypertension, effectively
acting as a strong vasodilator and promoter of pulmonary
regeneration.11
Several methods of gene transfection to the lungs have
been reported, but these methods have limitations and are
still controversial.11 However, the liver is a suitable organ
for gene transfection for the delivery of endocrine factors to
the lung.12-14 Therefore, because prostacyclin produced by
PGIS functions as an endocrine agent, we hypothesized that
the overexpression of PGIS in the liver might ameliorate
pulmonary hypertension by delivering prostacyclin to the
lungs.
In this study, we investigated whether transfection of the
PGIS gene to the liver results in prostacyclin delivery to the
lungs and whether this may be an effective treatment for
pulmonary hypertension induced by monocrotaline (MCT)
in rats.
Materials and Methods
Pulmonary Hypertension Model
Male Sprague-Dawley rats weighing approximately 200 g (Nihon
Animal, Osaka, Japan) were used. Pulmonary hypertension was
induced in the rats by a subcutaneous injection of MCT (60 mg/kg)
in the neck. After MCT injection, we confirmed that the right
ventricular systolic pressure rose gradually and reached the sys-
tolic pressure at the third week. The ratio of right ventricular to
femoral arterial pressure (RV/FA) increased over time. Four weeks
after the MCT injection, the right ventricular pressure appeared to
show a slight decrease, but the difference was not significant
(Figure 1). We used rats in the fourth week after MCT injection in
this study.
Experimental Protocols
Gene transfection. Twenty rats with induced pulmonary hy-
pertension were divided into the PGIS and control groups. An
additional 10 rats were added to each group for the analysis of
cumulative survival ratios. After the rats were anesthetized by an
intraperitoneal injection of pentobarbital (30 mg/kg), a small peri-
toneotomy of the upper abdomen was performed, exposing the
liver. Via a 27-gauge needle, 1 mL of a hemagglutinating virus of
Japan (HVJ)–liposome complex that included 75 g of plasmid
DNA was then injected into the liver.
Evaluation of hemodynamics after gene transfection. Hemo-
dynamics was evaluated 7 days after gene transfer. After the rats
were anesthetized by an intraperitoneal injection of pentobarbital,
tracheal intubation was performed with a polyethylene catheter,
and the intubation catheter was connected to a volume-regulated
respirator (Shinano model SN480-7; Shinano Mainichi Shimbun
Inc, Nagano, Japan) for mechanical ventilation (FIO2 0.21, rate 60
breaths/min). For measurement of the systemic arterial pressure, a
24-gauge Angiocath catheter (Becton Dickinson, Franklin Lakes,
NJ) was inserted into the left femoral artery, and the arterial line
was connected to a pressure transducer and polygraph. After
median sternotomy, a 26-gauge needle connected to a pressure line
was inserted into the right ventricle. The femoral arterial and right
ventricular pressures were recorded at the same time and the
RV/FA pressure ratio was calculated. After blood samples were
removed, the rat was killed by pentobarbital overdose, and the
liver, lungs, and heart were removed for histologic and protein
assays. The experimental protocols were approved by the animal
research committee of Osaka University Medical School.
Construction of Plasmid DNA
The expression vector for human PGIS was kindly provided by Dr
Tanabe (Department of Pharmacology, National Cardiovascular
Center). This plasmid was constructed by inserting the blunted
Hind III/Bam HI fragment of the full-length human PGIS cDNA
into the blunted Xho I site of the pUC/CAGGS expression plas-
mid.7
Preparation of HVJ Liposomes
The HVJ liposomes were prepared as described previously.15 In
brief, 10 mg of lipid mixture (phosphatidylcholine:dioleoylphos-
phatidyl ethanolamine:shingomyeline:cholesterol:phosphatidylser-
ine  13.3:13.3:13.3:50:10 in molar ratio) was dried by reversed-
phase evaporation. The dried lipid was then hydrated in 200 L of
balanced salt solution (BSS  137 mmol/L NaCl/5.4 mmol/L
KCl/10 mmol/L Tris HCl, pH 7.6). The PGIS expression plasmid
(200 g in 200 L BSS) or 200 L BSS alone (control vector) was
added. Liposomes were prepared by shaking and sonication. Pu-
rified HVJ (Z strain) was inactivated by ultraviolet irradiation (110
ergs  mm2  s1) for 3 minutes just before use. The liposome
Figure 1. The RV/FA pressure ratios after MCT injection were
shown. Black columns are the MCT group, and the white columns
are the control group, which received only injections of saline
solution. RV/FA pressure ratios were measured every week in 3
rats from each group. From 3 to 4 weeks after MCT injection, the
right ventricular pressure equaled the systemic pressure.
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suspension (0.5 mL, containing 10 mg of lipids) was mixed with
HVJ (15,000 hemagglutinating units) in a total volume of 4 mL of
BSS. The mixture was incubated at 4°C for 5 minutes and then for
60 minutes with gentle shaking at 37°C. Free HVJ was removed
from the HVJ liposomes by sucrose density gradient centrifuga-
tion. The top layer of the sucrose gradient, which contained the
HVJ liposomes, was collected. The HVJ liposomes were then
collected as a pellet by centrifugation at 19,350g at 4°C for 30
minutes and resuspended in 2 mL of BSS before use. This HVJ-
liposome solution was used for gene transfer with the addition of
CaCl2 (final concentration, 1 mmol/L). This preparation method
has been optimized to achieve maximal transfection efficiency, as
reported previously.
Enzyme Immunoassays for 6-Keto-prostaglandin F1,
Total Collagen, and Endothelin-1, and Bicinchoninic
Acid Assay for Protein
The level of 6-keto-prostaglandin F1, a stable hydrolyzed metab-
olite of prostacyclin, was analyzed with an enzyme immunoassay
kit (Assay Designs, Inc, Ann Arbor, Mich). The levels of total
collagen in lung tissue were analyzed with a Sircol collagen assay
kit (Biocolor Assays; Biocolor Ltd, Belfast, Northern Ireland). The
levels of endothelin-1 in lung tissues were analyzed with an
endothelin-1 EIA kit (Cayman Chemical Company, Ann Arbor,
Mich). Protein levels of the same tissues as those used for the total
collagen assays were measured with a bicinchoninic acid protein
assay kit (Pierce Chemical Company, Rockford, Ill). The amount
of total collagen or endothelin-1 in tissue is presented as a ratio to
the amount of total protein. All assays were carried out as de-
scribed by the manufacturers.
Immunohistological Analysis
Seven days after the transfer of PGIS expression plasmid or
control vector, the lungs and livers of the MCT rats were stained
immunohistochemically with a rabbit polyclonal antibody raised
against a partial sequence of the human PGIS sequence. Two-
micron–thick sections of paraffin-embedded tissues were prepared,
then de-paraffinized before staining. The sections were incubated
in 3% hydrogen peroxide for 30 minutes to block endogenous
peroxidase activity and to permeabilize the cells. Nonspecific
binding of rabbit serum was prevented by preincubating the sec-
tions with 0.2% normal goat serum. The sections were incubated at
4°C with rabbit antibody against human PGIS at a concentration of
1:1000 overnight and then with biotinylated goat anti-rabbit im-
munoglobulin G (Dako Japan Co Ltd, Kyoto, Japan) for 30 min-
utes, followed by peroxidase labeling with streptavidin (LSAB kit;
Dako Japan Co) for an additional 20 minutes at room temperature.
Each incubation was followed by washing in phosphate-buffered
saline solution with Tween 20. Staining was visualized with a
chromogen, 0.06% 3,3-diaminobenzidine/0.03% hydrogen perox-
ide in 8 mmol/L Tris-HCl (pH 6.85). Hematoxylin was used as a
counterstain. Control sections were incubated with nonimmune
rabbit immunoglobulin G at a concentration of 1:1000.
Western Blotting Analysis
Frozen tissues were homogenized with a Thyristor Regler TR50
(Janke & Kunkel IKA-WERK, Staufen, Germany) with RIPA
buffer (phosphate-buffered saline solution, 1% nonionic detergent
P-40, 0.5% sodium deoxycholate, 0.1% sodium lauryl sulfate, 1.1
mmol/L phenylmethylsulfonyl fluoride, and 5 ng/mL leupeptin).
The homogenized tissues were spun (200g, 20 minutes, Kubota
2010 centrifuge; ITS Science & Medical Pte Ltd, Singapore), and
the protein concentration of the supernatants was measured with a
bicinchoninic acid protein assay kit. Samples containing a similar
amount of total protein were combined with 5-L RIPA buffer,
10-L sodium dodecylsulfate sample buffer (BioLabs Co, Singa-
pore), and 1-L -mercaptoethanol (Wako, Japan), and were
incubated at 90°C for 5 minutes. The protein extracts were sepa-
rated on a 10% to 20% denaturing polyacrylamide gradient gel
(Multigel; Daiichi Pure Chemicals Co, Ltd, Tokyo, Japan), then
electrophoretically transferred to a Hybond-PVDF membrane
(ASSO Co). The membrane was blocked with 5% nonfat dry milk
in Tris-buffered saline solution containing 0.1% Tween-20. After
blocking, the membrane was incubated at room temperature with
the appropriate dilution of the rabbit polyclonal antibody (1:1000),
washed with triethanolamine-buffered saline solution containing
0.1% Tween-20, then incubated with a goat anti-rabbit immuno-
globulin G–horseradish peroxidase conjugate. After washing,
chemiluminescence was used to detect the protein bands (ECL kit;
Amersham Corp, Arlington Heights, Ill).
Statistical Analysis
All data are expressed as means  SEM unless otherwise indi-
cated. Parameters between the two groups were analyzed by an
unpaired Student t test. Survival curves between the two groups
were derived by means of the Kaplan-Meier method and compared
by log-rank tests.
Results
RV/FA Pressure Ratio
The RV/FA ratios and the RV/FA pressures after injection
of PGIS-HVJ liposomes or HVJ liposomes (without plas-
mid) are presented in Figure 2. After gene transfection, the
RV/FA pressure ratio decreased from approximately 1 to
0.596 in the PGIS group and from 1 to 0.879 in the control
group. The decrease in the RV/FA ratio was significantly
greater in the PGIS group than that in the control group
(PGIS vs control, 0.596  0.039 vs 0.879  0.051; P 
.0036).
6-Keto-Prostaglandin F1 Analysis
The results of blood analysis are shown in Figure 3. The
PGIS group showed significantly higher plasma levels of
6-keto-prostaglandin F1 than did the control group (PGIS
vs control, 35.43  4.42 ng/mL vs 22.34  3.33 ng/mL;
P  .0436).
Immunohistochemical Staining
The results of the immunohistologic analysis are presented
in Figure 4. The hepatic cells showed strong positive stain-
ing for PGIS only in the PGIS group. The PGIS-positive
cells were mainly located around the hepatic central veins.
In contrast, no or very little immunoreactivity was observed
in the control livers. No positive cells were observed in the
lungs of either group.
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Western Blot Analysis
The results of Western blotting are presented in Figure 5.
PGIS was expressed predominantly as a single band at
approximately 56 kD in the PGIS and control groups. How-
ever, PGIS was expressed at a significantly higher level in
the PGIS group than in the control group. In contrast, PGIS
expression was not detected in the lungs of either group
(lanes 3 and 4).
Collagen and Endothelin-1 in Lung
The concentration of endothelin-1 in the lung tissue was
significantly lower in the PGIS group than in the control
group (PGIS vs control, 10.42  2.01 pg/mg protein vs
19.94  2.82 pg/mg protein; P  .0176) (Figure 6, A).The
collagen concentration in the lung was compared between
the PGIS and control groups. The amount of total collagen
in the lung was less in the PGIS group than in the control
group, although the difference was not statistically signifi-
cant (PGIS vs control, 0.75 0.11 g/mg protein vs 1.05
0.21 g/mg protein; P  .192) (Figure 6, B).
Survival Ratio Analysis After PGIS Transfection
Survival curves generated by Kaplan-Meier analysis are
presented in Figure 7. The cumulative survival ratios were
0.511 for the PGIS group and 0.107 for the control group 60
days after MCT injection. The survival ratio was signifi-
cantly higher for the PGIS group than for the control group
(P  .0375).
Discussion
In this study, we demonstrated that transfer of the human
PGIS gene into the liver increased the prostacyclin level,
resulting in the amelioration of MCT-induced pulmonary
hypertension. Moreover, PGIS-transfected MCT rats
showed higher survival than the MCT rats that did not
receive the transgene. The PGIS-transfected group showed
significantly lower level of endothelin-1, a marker for lung
remodeling, in the lung. These data suggest that transfection
of the PGIS gene to the liver resulted in a drug delivery
system of prostacyclin for the lung, and therefore this may
be an effective treatment for pulmonary hypertension.
The conventional treatments for pulmonary hypertension
include calcium blockers, phosphodiesterase inhibitors, and
Figure 2. After the injection of PGIS cDNA, the RV/FA pressure ratios decreased significantly in the PGIS group
compared with the control group (PGIS vs control, 0.596  0.039 vs 0.879  0.051; P  .0036). There were no
significant differences in the femoral arterial pressures between the two groups (PGIS vs control, 83.6  6.9 mm
Hg vs 85.0  19.7 mm Hg; P  .937).
Figure 3. The plasma levels of 6 keto-PG F1 in the PGIS gene-
transfected group were significantly higher than in the control
group (PGIS vs control, 35.43  4.42 pg/mL vs 23.34  3.33 pg/mL;
P  .0436).
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inhaled nitric oxide.16 Although aerosolized prostacyclin
has been suggested for selective pulmonary vasodilation,
similar to inhaled nitric oxide, its effect rapidly drops after
the nebulization treatment.17 The long-term continuous in-
travenous administration of prostacyclin analogs has also
been reported to be effective for primary and secondary
pulmonary hypertension,2-4 but it is difficult to continue
such therapy in a clinical setting. As a general pharmaco-
logic principle to treat pulmonary hypertension, combina-
tions that produce similar effects via different mechanisms,
such as inhaled nitric oxide, calcium blockers, phosphodi-
esterase inhibitors, and prostacyclin analogs, appear to have
additive or synergistic effects. However, such combination
therapy is still limited in its effectiveness over the long term.
Increasing the production of intrinsic prostacyclin as a
drug delivery system seems to be useful. For example,
Geraci and colleagues18 reported that overexpression of
PGIS in the lungs of transgenic mice attenuated the devel-
Figure 4. Immunohistochemical staining was performed with an anti-human prostaglandin I2 synthase antibody.
Immuno-positive cells were found around central veins in the PGIS group (A) but not in the control group (B). No
positive cells were found in the lung in either the PGIS or control group. (Original magnification 400.)
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opment of hypoxic pulmonary hypertension. On the other
hand, we thought that gene transfer of PGIS would be useful
in clinical settings and that gene transfection into the liver as
a drug delivery organ would enable stable and less-invasive
treatments for pulmonary hypertension.
Intratracheal inhalation methods have also been reported
to be useful for gene transfection to the lungs.11,19 Although
this method appears to be convenient for clinical applica-
tion, it has limitations, such as limited areas of transfection
in the lung and low efficiency of transfection into endothe-
lial cells, and it causes deterioration of respiratory function,
especially in critically ill patients.20,21 Moreover, aerosol-
ized plasmid-vector complexes in the air expelled by the
patients can introduce undesirable pollutants into the air,
where they can be inhaled by others.
In contrast, transfection of PGIS to the liver avoids these
problems. Here, we showed prostacyclin from PGIS trans-
fected into the liver could be delivered to the pulmonary
artery via hepatic veins, the inferior vena cava, right atrium,
and right ventricle as a drug delivery system for the lung. It
Figure 6. A, The levels of endothelin-1 in lung tissue were determined. PGIS versus control, 10.42  2.01 pg/mg
protein versus 19.94  2.82 pg/mg protein. B, The amount of total collagen in lung tissue was determined. PGIS
versus control, 0.75  0.11 g/mg protein versus 1.05  0.21 g/mg protein; P  .192).
Figure 7. Survival ratios were analyzed by the Kaplan-Meier
method. The survival ratios were significantly higher in the PGIS
group than in the control group (log-rank test, P  .0375).
Figure 5. Western blotting was performed with an anti-human prostaglandin I2 synthase antibody. First lane,
Control (liver); second lane, PGIS (liver); third lane, control (lung); fourth lane, PGIS (lung). Overexpression of
prostaglandin I2 synthase protein in the transfected liver of the PGIS group was confirmed (56-kD band). However,
the expression of PGIS protein in the lung was not found for the PGIS group.
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appears that gene transfection via such a hepatic approach
could be performed safely in clinical settings, even in pa-
tients with poor respiratory function. In our study, none of
the rats showed any adverse effects from the treatment,
including low blood pressure and liver dysfunction. Al-
though further investigations are needed, hepatic delivery
system of prostacyclin with PGIS seems to be a potentially
useful application of gene therapy.
The efficient intratracheal transfer of the human PGIS
gene at the same time as MCT injection was previously
reported to prevent the progression of the MCT-induced
pulmonary hypertension in rats.11 However, it has not yet
been determined whether the PGIS gene transfection by
intratracheal inhalation was efficient enough to ameliorate
advanced pulmonary hypertension in the chronic phase. In
our study, a high pulmonary arterial pressure equal to the
systemic arterial pressure was significantly decreased by
PGIS gene transfection during the chronic phase of MCT-
induced pulmonary hypertension. Although no morphologic
changes were detected in the pulmonary vessels, decreases
in endothelin-1 in the lung tissue were detected 7 days after
PGIS gene transfection. It may demonstrate that PGIS gene
transfection also indirectly affects the biologic responses via
cyclic guanosine monophosphate receptors, on which endo-
thelin and nitric oxide act. The concentration of total colla-
gen in the lung showed a slightly lower level in the PGIS
group. A longer follow-up is required to confirm whether
PGIS transfection improves the regeneration of lung tissues
in advanced pulmonary hypertension.
In the clinical setting, percutaneous liver injection, such
as percutaneous ethanol injection therapy, has been per-
formed in general surgery with ultrasonography as a treat-
ment for hepatoma. Therefore, the percutaneous injection of
genes into the liver may be performed safely and effectively
by such techniques. However, Brigham and Stecenko21
pointed out that gene therapy for a treatment of lung dis-
eases has not yet been adopted clinically, as had been
expected. They indicated that the reason was difficulty in
coping with both its safety and efficacy as for the viral or
nonviral vectors and delivery systems.21 Although HVJ
liposome was used as a transfection method in this study, its
durability of transfection may have limitations the same as
adenovirus vector or the liposome method. In addition, the
side effects associated with the increased prostaglandin I2
levels are still unknown. Further study, including the search
for better vectors and delivery technologies, is needed to
optimize the conditions for PGIS gene transfer to prolong
the overexpression of PGIS with minimal or no side effects.
In conclusion, gene transfer of human prostacyclin syn-
thase into the liver may be an alternative for the treatment of
pulmonary hypertension in the future.
We thank Akiko Nishimura and Shigeru Matsumi for their
technical assistance.
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